We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+13.54%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.12B
AUM Growth
-$493M
Cap. Flow
-$785M
Cap. Flow %
-15.35%
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$101M
2
RLAY icon
Relay Therapeutics
RLAY
+$70.2M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$59.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$39.8M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$33.2M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$122M
2
ACLX
Arcellx
ACLX
+$95.6M
3
BSX icon
Boston Scientific
BSX
+$93.3M
4
FOLD
Amicus Therapeutics
FOLD
+$90.7M
5
ATXS
Astria Therapeutics
ATXS
+$84.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
101
Boston Scientific
BSX
$66.3B
– –
-979,000
Closed -$93.3M
CAPR icon
102
CALL
Capricor Therapeutics
CAPR
$1.11B
– –
-242,100
Closed -$6.99M
CDTX
103
DELISTED
Cidara Therapeutics
CDTX
– –
-165,131
Closed -$36.5M
CVS icon
104
CVS Health
CVS
$136B
– –
-220,000
Closed -$17.5M
DHR icon
105
Danaher
DHR
$145B
– –
-200,000
Closed -$45.8M
DXCM icon
106
DexCom
DXCM
$30.1B
– –
-225,758
Closed -$15M
EXAS
107
DELISTED
Exact Sciences
EXAS
– –
-1,200,487
Closed -$122M
FOLD
108
DELISTED
Amicus Therapeutics
FOLD
– –
-6,370,851
Closed -$90.7M
GKOS icon
109
Glaukos
GKOS
$9.13B
– –
-140,000
Closed -$15.8M
GOSS icon
110
Gossamer Bio
GOSS
$83.3M
– –
-3,139,669
Closed -$9.73M
IMMX icon
111
Immix Biopharma
IMMX
$716M
– –
-338,941
Closed -$1.77M
IOVA icon
112
Iovance Biotherapeutics
IOVA
$2.08B
– –
-152,714
Closed -$417K
IRON icon
113
Disc Medicine
IRON
$2.81B
– –
-450,743
Closed -$35.8M
KOD icon
114
Kodiak Sciences
KOD
$2.58B
– –
-848,900
Closed -$23.7M
KRYS icon
115
Krystal Biotech
KRYS
$10.1B
– –
-17,500
Closed -$4.31M
KYMR icon
116
Kymera Therapeutics
KYMR
$9.38B
– –
-69,935
Closed -$5.44M
LXEO icon
117
Lexeo Therapeutics
LXEO
$358M
– –
-139,835
Closed -$1.39M
MIRM icon
118
Mirum Pharmaceuticals
MIRM
$7.16B
– –
-259,545
Closed -$20.5M
NVNO
119
enVVeno Medical
NVNO
$6.85M
– –
-50,258
Closed -$564K
OLMA icon
120
Olema Pharmaceuticals
OLMA
$967M
– –
-165,713
Closed -$4.14M
PEN icon
121
Penumbra
PEN
$12.6B
– –
-110,529
Closed -$34.4M
PEPG icon
122
PepGen
PEPG
$156M
– –
-829,870
Closed -$5.4M
RAPT
123
DELISTED
RAPT Therapeutics
RAPT
– –
-825,890
Closed -$28M
SDGR icon
124
Schrodinger
SDGR
$1.17B
– –
-202,400
Closed -$3.62M
SVRA icon
125
Savara
SVRA
$1.13B
– –
-2,400,000
Closed -$14.5M
2 3 4
5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $785M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.

  • Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
  • Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
  • Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
  • Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
  • Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.